Drug intelligence / Profile preview

D1K

Development stage: Preclinical
Lead developer: Ensol Biosciences
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides

Overview

D1K is a peptide-drug conjugate (PDC) currently in preclinical development by Ensol Biosci for the treatment of cancer. The drug candidate is designed to leverage the specificity of a targeting peptide to deliver a cytotoxic or therapeutic payload directly to tumor cells, potentially enhancing efficacy while reducing systemic toxicity compared to traditional chemotherapy. As of early 2024, the specific molecular target and payload of D1K have not been publicly disclosed, but it represents a key part of Ensol Biosci's innovative oncology pipeline.

Targets

DCLK1 (Doublecortin-like kinase 1)

Beyond the preview

Go deeper on D1K.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D1K.

Explore the full profile